Title |
Electronic applications for the CFQ-R scoring
|
---|---|
Published in |
Respiratory Research, May 2017
|
DOI | 10.1186/s12931-017-0592-z |
Pubmed ID | |
Authors |
Andreas Ronit, Marco Gelpi, Jonathan Argentiero, Inger Mathiesen, Susanne D. Nielsen, Tanja Pressler, Alexandra L. Quittner |
Abstract |
Patient reported outcomes (PROs) have become widely accepted outcome measures in cystic fibrosis (CF) and other respiratory diseases. The Cystic Fibrosis-Questionnaire-Revised (CFQ-R) is the best validated and most widely used PRO for CF. Data collection can be time-intensive, and electronic platforms would greatly facilitate the feasibility, utility and accuracy of administration of the CFQ-R. Given that the CFQ-R is utilized in virtually all clinical trials worldwide and is increasingly integrated into clinical practice, we developed a software application that will help users to administer, score and save CFQ-R data for all versions. All codes are open access, which will enable other PRO users to design similar applications for other respiratory diseases, such as primary ciliary dyskinesia and non-CF bronchiectasis. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 2 | 50% |
Moldova, Republic of | 1 | 25% |
Unknown | 1 | 25% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 75% |
Scientists | 1 | 25% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 47 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 12 | 26% |
Student > Ph. D. Student | 5 | 11% |
Other | 4 | 9% |
Student > Postgraduate | 3 | 6% |
Researcher | 2 | 4% |
Other | 6 | 13% |
Unknown | 15 | 32% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 17 | 36% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
Biochemistry, Genetics and Molecular Biology | 2 | 4% |
Nursing and Health Professions | 2 | 4% |
Economics, Econometrics and Finance | 2 | 4% |
Other | 7 | 15% |
Unknown | 15 | 32% |